<DOC>
	<DOCNO>NCT02821689</DOCNO>
	<brief_summary>Interstitial lung disease ( ILD ) common complication dermatomyositis ( DM ) prevalence 65 % , consider one determine factor prognosis . Clinical amyopathic dermatomyositis ( CADM ) , special phenotype DM , characteristic cutaneous manifestation subclinical myopathy . Many study , mainly Asia , include , demonstrate patient CADM tend develop rapidly progressive ILD ( RPILD ) poor response conventional therapy , high-dose corticosteroid immunosuppressant , lead lethal outcome 6-month survival rate le 50 % . Pirfenidone , new oral antifibrotic agent , approve treatment idiopathic pulmonary fibrosis ( IPF ) . Randomized controlled trial pirfenidone patient IPF suggest could ameliorate pulmonary function decline improve progression-free survival . Its utility connective tissue disease ( CTD ) relate ILD implicate , evidence yet demonstrate efficacy . Therefore , investigator conduct study evaluate possible therapeutic effect pirfenidone RPILD associate CADM .</brief_summary>
	<brief_title>Pirfenidone Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Willingness subject participate study , proven sign informed consent ; All participant fulfil provisional diagnosis CADM accord modify Sontheimer 's criterion . The course ILD longer 3 month , short 6 month , present increase level dyspnea , worsen fibrosis pulmonary HRCT &gt; 10 % increase HRCT score , and/or decrease % FVC &gt; 10 % absolute value . Participants unwilling sign inform consent ; The course participant ever treat biologics include basiliximab , malignancyassociated CADM overlap CTD , alanine transaminase 2 time upper normal limit ; Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Dermatopolymyositis</keyword>
	<keyword>Interstitial lung disease</keyword>
	<keyword>Pirfenidone</keyword>
</DOC>